11/17
08:41 am
rnaz
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer [Yahoo! Finance]
Low
Report
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer [Yahoo! Finance]
11/17
08:01 am
rnaz
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
Low
Report
TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer
10/25
12:13 pm
rnaz
TransCode Therapeutics (NASDAQ:RNAZ) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
TransCode Therapeutics (NASDAQ:RNAZ) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
10/14
08:42 am
rnaz
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO [Yahoo! Finance]
Low
Report
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO [Yahoo! Finance]
10/14
08:06 am
rnaz
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
High
Report
TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO
10/8
08:24 am
rnaz
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company [Yahoo! Finance]
Medium
Report
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company [Yahoo! Finance]
10/8
08:01 am
rnaz
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
High
Report
TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company